Compare NX & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NX | AMPH |
|---|---|---|
| Founded | 1927 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 852.1M | 971.8M |
| IPO Year | 2008 | 2005 |
| Metric | NX | AMPH |
|---|---|---|
| Price | $17.02 | $18.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $28.00 | ★ $28.38 |
| AVG Volume (30 Days) | 267.3K | ★ 580.8K |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | ★ $1,837,641,000.00 | $719,887,000.00 |
| Revenue This Year | $4.26 | $6.90 |
| Revenue Next Year | $1.77 | $4.64 |
| P/E Ratio | ★ N/A | $127.14 |
| Revenue Growth | ★ 43.81 | N/A |
| 52 Week Low | $11.04 | $16.65 |
| 52 Week High | $22.90 | $31.26 |
| Indicator | NX | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 36.09 | 39.14 |
| Support Level | $16.61 | $17.03 |
| Resistance Level | $20.24 | $24.16 |
| Average True Range (ATR) | 0.82 | 0.88 |
| MACD | -0.41 | -0.40 |
| Stochastic Oscillator | 25.73 | 17.60 |
Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.